Local vascular changes induced by the cocarcinogen, phorbol myristate acetate.
D000085:Acetates; D000818:Animals; D001551:Benz(a)Anthracenes; D002273:Carcinogens; D004423:Ear; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D006940:Hyperemia / Q000139:chemically induced / Q000188:drug therapy; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D007659:Ketones / Q000627:therapeutic use; D007705:Kinins / Q000037:antagonists & inhibitors; D008407:Mast Cells / Q000473:pathology; D051379:Mice; D010649:Phenylalanine / Q000627:therapeutic use; D012702:Serotonin Antagonists; D012711:Serum Albumin, Radio-Iodinated; D012867:Skin / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy
D000085:Acetates; D001551:Benz(a)Anthracenes; D002273:Carcinogens; D006634:Histamine H1 Antagonists; D007659:Ketones; D007705:Kinins; D012702:Serotonin Antagonists; D012711:Serum Albumin, Radio-Iodinated; D010649:Phenylalanine; D006854:Hydrocortisone